ew data presented today at the European League
Against Rheumatism Annual Congress (EULAR 2014) show that the newly - approved
infliximab biosimilar CT - P13 achieves statistically similar improvements in disease activity, disability and mobility in patients with Ankylosing Spondylitis (AS) compared to its original reference product
infliximab (INX).